z-logo
open-access-imgOpen Access
Text Mining-Based Drug Discovery in Osteoarthritis
Author(s) -
Rong-Guo Yu,
Jiayu Zhang,
Zhentao Liu,
Youguang Zhuo,
Haiyang Wang,
Jie Ye,
Nannan Liu,
Yiyuan Zhang
Publication year - 2021
Publication title -
journal of healthcare engineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.509
H-Index - 29
eISSN - 2040-2309
pISSN - 2040-2295
DOI - 10.1155/2021/6674744
Subject(s) - drug discovery , osteoarthritis , drug , data science , medicine , medline , computer science , bioinformatics , alternative medicine , pharmacology , biology , pathology , biochemistry
Background Osteoarthritis (OA) is a chronic and degenerative joint disease, which causes stiffness, pain, and decreased function. At the early stage of OA, nonsteroidal anti-inflammatory drugs (NSAIDs) are considered the first-line treatment. However, the efficacy and utility of available drug therapies are limited. We aim to use bioinformatics to identify potential genes and drugs associated with OA.Methods The genes related to OA and NSAIDs therapy were determined by text mining. Then, the common genes were performed for GO, KEGG pathway analysis, and protein-protein interaction (PPI) network analysis. Using the MCODE plugin-obtained hub genes, the expression levels of hub genes were verified using quantitative real-time polymerase chain reaction (qRT-PCR). The confirmed genes were queried in the Drug Gene Interaction Database to determine potential genes and drugs.Results The qRT-PCR result showed that the expression level of 15 genes was significantly increased in OA samples. Finally, eight potential genes were targetable to a total of 53 drugs, twenty-one of which have been employed to treat OA and 32 drugs have not yet been used in OA.Conclusions The 15 genes (including PTGS2, NLRP3, MMP9, IL1RN, CCL2, TNF, IL10, CD40, IL6, NGF, TP53, RELA, BCL2L1, VEGFA, and NOTCH1) and 32 drugs, which have not been used in OA but approved by the FDA for other diseases, could be potential genes and drugs, respectively, to improve OA treatment. Additionally, those methods provided tremendous opportunities to facilitate drug repositioning efforts and study novel target pharmacology in the pharmaceutical industry.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom